In 2014, the Irish biopharmaceutical company GreenLight Pharmaceuticals Ltd was established, which focuses on the development of safe and effective herbal medicines. GreenLight specializes in phytocannabinoid research.







The company is based in Dublin, but has recently set up another headquarters, specifically in Britain. Their next goal is to expand the availability of medical cannabis throughout Europe.

' Therapeutic cannabis' (cannabis-based medical products (CBMP)) includes a wide range of products that contain active compounds (primarily THC and CBD). These can be formed chemically, obtained from the plant, but can also be obtained in other ways.

Clinical evidence of the use of medical cannabis


Evidence regarding the use of medical cannabis and its effectiveness is based on controlled tests . The most significant evidence comes from tests that focused on multiple sclerosis, pain and epilepsy.


Multiple Sclerosis (MS)

People with multiple sclerosis who have received doses of nabiximol (sativex) as an adjunct to treatment confirm that they have experienced a reduction in muscle tension.


Chronic pain

Chronic pain, which includes neuropathic and musculoskeletal pain, is the main reason why people opt for medical cannabis. One study confirms that test subjects experienced a 30% reduction in pain.


Epilepsy

To date, 261 people with epilepsy have participated in the largest CBD study. The average age was 11 years. After three months of combination therapy (CBD + regular medicines), the frequency of seizures decreased by 45%.


GreenLight is currently focusing on eight therapeutic studies in the following areas:

- neurological problems including Alzheimer's disease, addiction and pain
- inflammatory diseases including arthritis, arthritis-related depression, visual disturbances and diabetes
- cancer, including prostate


Article author: David Gibson, PhD (Chief Scientific Officer), GreenLight
Article source: www.healtheuropa.eu
Photo source: pixabay.com (authors: meineresterampe, FotoshopTofs)